{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:06Z","timestamp":1790208006236,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ50295, 2024JJ7593"],"award-info":[{"award-number":["2023JJ50295, 2024JJ7593"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SUV39H2, a histone methyltransferase involved in H3K9 trimethylation and transcriptional silencing, has been implicated in cancer progression. However, its expression patterns, clinical relevance, and functional roles in various tumor types remain to be fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SUV39H2 expression in multiple cancers and paired adjacent normal tissues was analyzed using the TCGA-GTEX database and Xiantao online tools. Prognostic significance was assessed by survival analysis. KEGG and GO enrichment analyses were conducted to explore potential functional roles. Immune infiltration correlations were evaluated based on TCGA data. Single-cell RNA sequencing from GSE176078 was analyzed for validation of expression patterns. Immunohistochemistry (IHC) was performed on five pairs of TNBC patient samples to confirm SUV39H2 expression. Western blotting (WB) was conducted to verify SUV39H2 knockdown efficiency in MDA-MB-231 and Hs-578T TNBC cells. Functional assays, including Transwell migration, colony formation, sphere formation, and subcutaneous xenograft tumorigenicity assays, were performed to evaluate the effects of SUV39H2 knockdown on TNBC cell growth and metastatic potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SUV39H2 was significantly overexpressed in multiple cancers, with consistently elevated levels in paired tumor-adjacent tissues. In TNBC, SUV39H2 expression was markedly upregulated across all clinical and TNM stages compared with normal tissues and other BRCA subtypes. Immunohistochemistry confirmed SUV39H2 overexpression in TNBC patient samples, and WB demonstrated successful knockdown in MDA-MB-231 and Hs-578T cells. Functional assays revealed that SUV39H2 knockdown significantly inhibited proliferation, migration, stemness, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      tumorigenicity in TNBC cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      SUV39H2 is consistently upregulated in triple-negative breast cancer and is associated with malignant features including enhanced proliferation, migration, stemness, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      tumorigenicity. Functional and clinical evidence highlights SUV39H2 as a potential diagnostic biomarker and therapeutic target in TNBC, although its clinical utility requires further validation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1679640","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:13Z","timestamp":1767331453000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of SUV39H2 in shaping the malignant phenotype of triple-negative breast cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhi-Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Fu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s44178-022-00007-8","article-title":"CACA guidelines for holistic integrative management of breast cancer","volume":"1","author":"Wu","year":"2022","journal-title":"Holist Integr Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths","volume":"10","author":"Xu","year":"2023","journal-title":"Sci Data"},{"key":"B7","doi-asserted-by":"publisher","first-page":"108253","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1515\/med-2020-0138","article-title":"A review of current progress in triple-negative breast cancer therapy","volume":"15","author":"Shen","year":"2020","journal-title":"Open Med (Wars)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23243","article-title":"The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999\u20132004","volume":"112","author":"Brown","year":"2008","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andr\u00e9","year":"2012","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1524-4741.2011.01175.x","article-title":"The paradox of triple negative breast cancer: novel approaches to treatment","volume":"18","author":"Fornier","year":"2012","journal-title":"Breast J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2760918","DOI":"10.1155\/2018\/2760918","article-title":"Identification of key genes and pathways in triple-negative breast cancer by integrated bioinformatics analysis","volume":"2018","author":"Dong","year":"2018","journal-title":"BioMed Res Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2569","article-title":"Immunotherapy for breast cancer: what are we missing","volume":"23","author":"Vonderheide","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3478","article-title":"Immune gene expression is associated with genomic aberrations in breast cancer","volume":"77","author":"Safonov","year":"2017","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31272","article-title":"Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here","volume":"124","author":"Kwa","year":"2018","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13696","article-title":"Triple-negative breast cancer-Role of immunology: A systemic review","volume":"26","author":"Oner","year":"2020","journal-title":"Breast J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1471-2407-12-306","article-title":"The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients","volume":"12","author":"Medrek","year":"2012","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.24.9423-9433.2000","article-title":"Isolation and characterization of Suv39h2, a second histone H3 methyltransferase gene that displays testis-specific expression","volume":"20","author":"O'Carroll","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.039","article-title":"New nomenclature for chromatin-modifying enzymes","volume":"131","author":"Allis","year":"2007","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbagrm.2014.11.005","article-title":"Activity and specificity of the human SUV39H2 protein lysine methyltransferase","volume":"1849","author":"Schuhmacher","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ng1278","article-title":"Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases","volume":"36","author":"Garc\u00eda-Cao","year":"2004","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/35065132","article-title":"Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins","volume":"410","author":"Lachner","year":"2001","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b01076","article-title":"The SUV39H1 protein lysine methyltransferase methylates chromatin proteins involved in heterochromatin formation and VDJ recombination","volume":"12","author":"Kudithipudi","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng.99","article-title":"PRC1 and Suv39h specify parental asymmetry at constitutive heterochromatin in early mouse embryos","volume":"40","author":"Puschendorf","year":"2008","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv013","article-title":"Alternative splicing regulates the expression of G9A and SUV39H2 methyltransferases, and dramatically changes SUV39H2 functions","volume":"43","author":"Mauger","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208619","article-title":"Pocket proteins and cell cycle control","volume":"24","author":"Cobrinik","year":"2005","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600074","article-title":"A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells","volume":"23","author":"Ait-Si-Ali","year":"2004","journal-title":"EMBO J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nsmb.2271","article-title":"p53-mediated heterochromatin reorganization regulates its cell fate decisions","volume":"19","author":"Mungamuri","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058183","article-title":"Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model","volume":"8","author":"Franci","year":"2013","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2967","article-title":"Genetic alterations of histone lysine methyltransferases and their significance in breast cancer","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013732","article-title":"Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus","volume":"5","author":"Li","year":"2010","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/jca.28254","article-title":"The oncogenic potential of SUV39H2: A comprehensive and perspective view","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044226","article-title":"NUF2 promotes breast cancer development as a new tumor stem cell indicator","volume":"24","author":"Deng","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/ng789","article-title":"Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin","volume":"30","author":"Peters","year":"2002","journal-title":"Nat Genet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13148-018-0562-4","article-title":"Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma","volume":"10","author":"Zheng","year":"2018","journal-title":"Clin Epigenet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12935-019-0982-z","article-title":"Histone methyltransferase SUV39H2 regulates cell growth and chemosensitivity in glioma via regulation of hedgehog signaling","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"27","author":"Ogata","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1113","article-title":"The Gene Ontology resource: enriching a GOld mine","volume":"49","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1679640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:14Z","timestamp":1767331454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1679640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":45,"alternative-id":["10.3389\/fonc.2025.1679640"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1679640","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1679640"}}